NCT05570825

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Recruiting now Phase 2 Last updated 4 December 2025

What this trial tests

Phase 2 trial testing Biopsy in Metastatic Lung Non-Small Cell Carcinoma in 30 participants. Currently enrolling.

Timeline

6 April 2023

Primary endpoint
1 July 2027

1 July 2028

Quick facts

Lead sponsor	University of Washington
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	6 April 2023
Primary completion	1 July 2027
Estimated completion	1 July 2028
Sites	1 location across United States

Drugs / interventions tested

• Biopsy — full drug profile →
• Biospecimen Collection — full drug profile →
• Computed Tomography
• CXCR1/2 Inhibitor SX-682 — full drug profile →
• Magnetic Resonance Imaging
• Pembrolizumab (pembrolizumab) — full drug profile →
• Positron Emission Tomography

Conditions studied

• Metastatic Lung Non-Small Cell Carcinoma — all drugs for Metastatic Lung Non-Small Cell Carcinoma →
• Recurrent Lung Non-Small Cell Carcinoma — all drugs for Recurrent Lung Non-Small Cell Carcinoma →
• Stage IIIC Lung Cancer AJCC v8 — all drugs for Stage IIIC Lung Cancer AJCC v8 →
• Stage IV Lung Cancer AJCC v8 — all drugs for Stage IV Lung Cancer AJCC v8 →

Sponsor

University of Washington

Who can join

18 and older, any sex, with Metastatic Lung Non-Small Cell Carcinoma or Recurrent Lung Non-Small Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests whether CXCR1/2 inhibitor SX-682 (SX-682) with pembrolizumab works to treat patients with stage IIIC or IV non-small cell lung cancer that has spread to other parts of the body (metastatic) or that has come back (recurrent). SX-682 is a drug that binds to receptors on some types of immune and cancer cells, inhibiting signaling pathways, reducing inflammation, and allowing other types of immune cells to kill and eliminate cancer cells. Pembrolizumab is a monoclonal antibody that binds to a receptor called PD-1 that is found on the surface of T-cells (a type of immune cell), activating an immune response against tumor cells. Giving SX-682 in combination with pembrolizumab may be more effective at treating patients with metastatic or recurrent non-small cell lung cancer than giving these treatments alone.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting cytokine and chemokine signaling pathways for cancer therapy.
   Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
2. Neutrophils at the Crossroads: Unraveling the Multifaceted Role in the Tumor Microenvironment.
   Awasthi D, Sarode A. · · 2024 · cited 41× · PMID 38474175 · DOI 10.3390/ijms25052929
3. Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity.
   Zhou Y, Shen G, Zhou X, Li J. · · 2025 · cited 39× · PMID 40461514 · DOI 10.1038/s41392-025-02242-7
4. Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms.
   Yao J, Ji L, Wang G, Ding J. · · 2025 · cited 26× · PMID 39485719 · DOI 10.1002/cac2.12613
5. LAG-3 : recent developments in combinational therapies in cancer.
   Chavanton A, Mialhe F, Abrey J, Baeza Garcia A, et al · · 2024 · cited 25× · PMID 38702996 · DOI 10.1111/cas.16205
6. Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies.
   Zhang M, Qin H, Wu Y, Gao Q. · · 2024 · cited 23× · PMID 39297568 · DOI 10.20892/j.issn.2095-3941.2024.0192
7. Exploring neutrophil extracellular traps: mechanisms of immune regulation and future therapeutic potential.
   Gao F, Peng H, Gou R, Zhou Y, et al · · 2025 · cited 18× · PMID 40442839 · DOI 10.1186/s40164-025-00670-3
8. Immune Cell Migration to Cancer.
   Ryan AT, Kim M, Lim K. · · 2024 · cited 16× · PMID 38786066 · DOI 10.3390/cells13100844